- Published on
Medicine – Important Fungal Infections: Yeasts, Candida Species and Cryptococcus
1. Introduction to Yeast Infections
Yeasts are a group of fungi that typically exist as single-celled, round or oval microorganisms. Unlike filamentous fungi, which predominantly grow as branching hyphae, yeasts usually reproduce by budding. However, some yeasts, particularly Candida species, can also form pseudohyphae or true hyphae under appropriate conditions.
Yeasts are medically important because they can cause infections ranging from superficial mucosal disease to severe systemic infections involving the bloodstream, brain and other internal organs.
The two major groups highlighted in these notes are Candida species and Cryptococcus species.
Candida commonly causes infections of the oral cavity, oesophagus, vagina and bloodstream. Cryptococcus is particularly important because it can cause pulmonary infection and life-threatening meningoencephalitis, especially in immunocompromised individuals.
The severity of fungal infection depends on the fungal species, the anatomical site involved, the integrity of mucosal barriers and the patient’s immune status.
Candida Species
2. Introduction to Candida
Candida is a genus of opportunistic fungi that can exist as part of the normal human microbiota.
Candida species commonly colonise the oral cavity, gastrointestinal tract, genital tract and skin without causing disease.
In healthy individuals, the normal bacterial microbiota, intact epithelial barriers and immune system help prevent excessive fungal proliferation.
However, disruption of these protective mechanisms can allow Candida to multiply and produce symptomatic infection.
Important predisposing factors include broad-spectrum antibiotic use, corticosteroid treatment, diabetes mellitus, immunosuppression, neutropenia and disruption of mucosal barriers.
Candida infections are collectively known as candidiasis.
3. Important Candida Species
Candida albicans is a major cause of human candidiasis and is particularly associated with oral, oesophageal and vulvovaginal infections.
Other clinically important species include Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei, now also known as Pichia kudriavzevii.
These species differ in their susceptibility to antifungal medications.
For example, Candida glabrata may have reduced susceptibility to fluconazole, while Candida krusei is intrinsically resistant to fluconazole.
Candida auris is another important species because it can cause healthcare-associated outbreaks, invasive infections and resistance to multiple antifungal drugs.
Species identification is particularly important in invasive candidiasis because it can influence antifungal treatment.
4. Morphological Characteristics of Candida
Candida species typically appear as oval budding yeast cells on microscopy.
Candida albicans can form budding yeast cells, pseudohyphae and true hyphae, depending on environmental conditions.
Pseudohyphae consist of elongated budding cells that remain attached to one another, producing structures resembling fungal filaments.
True hyphae are elongated tubular structures with relatively parallel walls.
The ability to switch between yeast and filamentous forms contributes to the pathogenicity of Candida albicans by facilitating tissue adherence, invasion and immune evasion.
A classical laboratory feature of Candida albicans is its ability to produce germ tubes under suitable laboratory conditions.
5. Pathogenesis of Candidiasis
Candida infection usually develops when the balance between fungal colonisation and host defence mechanisms is disrupted.
Broad-spectrum antibiotics can reduce the normal bacterial microbiota, allowing Candida to proliferate.
Corticosteroids suppress local or systemic immune responses and may increase susceptibility to fungal infection.
Immunodeficiency, including advanced HIV infection and neutropenia, can impair the ability to control Candida growth.
Invasive candidiasis may occur when Candida enters the bloodstream through damaged mucosal surfaces or intravascular devices.
The resulting clinical disease depends on whether Candida remains confined to superficial tissues or spreads into normally sterile body sites.
Oral Candidiasis
6. Introduction to Oral Candidiasis
Oral candidiasis, commonly called oral thrush, is a fungal infection affecting the oral mucosa.
It is most commonly caused by Candida albicans, although other Candida species may also be responsible.
Oral thrush occurs when Candida proliferates excessively on the mucosal surfaces of the mouth.
It is particularly common in infants, older adults, patients using inhaled corticosteroids and individuals with impaired immune function.
Oral candidiasis can also occur following broad-spectrum antibiotic treatment.
7. Clinical Features of Oral Candidiasis
The classical presentation of oral candidiasis is the development of creamy-white, plaque-like lesions on the tongue, palate, buccal mucosa or other oral surfaces.
In pseudomembranous candidiasis, these plaques can usually be scraped away, leaving an erythematous or occasionally bleeding mucosal surface.
Patients may experience oral discomfort, burning sensations, altered taste and difficulty eating.
Some patients develop erythematous candidiasis, in which the oral mucosa appears red and inflamed without prominent white plaques.
Angular cheilitis may also occur, producing inflammation and fissuring at the corners of the mouth.
The characteristic examination finding is removable white oral plaques associated with Candida infection.
8. Risk Factors for Oral Candidiasis
Broad-spectrum antibiotic therapy is an important risk factor because it reduces competing bacterial populations within the oral cavity.
Corticosteroid therapy, particularly inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease, may suppress local mucosal immunity.
Patients who do not rinse their mouths after using inhaled corticosteroids are at increased risk.
Other risk factors include diabetes mellitus, denture use, dry mouth, malnutrition, HIV infection and other causes of immunosuppression.
Persistent, severe or recurrent oral candidiasis should prompt consideration of an underlying predisposing condition.
9. Oral Candidiasis and Inhaled Corticosteroids
Inhaled corticosteroids are commonly used in the management of asthma and selected patients with chronic obstructive pulmonary disease.
A proportion of the inhaled medication may deposit on the oral and pharyngeal mucosa.
This can suppress local immune defences and encourage Candida proliferation.
Patients may develop oral thrush, hoarseness or throat irritation.
The risk can be reduced by rinsing the mouth and spitting out the water after inhaled corticosteroid use. A spacer device may also reduce oropharyngeal deposition with compatible metered-dose inhalers.
10. Diagnosis of Oral Candidiasis
Oral candidiasis is often diagnosed clinically from the characteristic appearance of mucosal lesions and the presence of relevant risk factors.
When the diagnosis is uncertain, a sample may be examined microscopically using potassium hydroxide or other appropriate fungal stains.
Microscopy may demonstrate budding yeast cells and pseudohyphae.
Fungal culture is not routinely required for straightforward cases because Candida can colonise the oral cavity without causing disease.
Culture or species identification may be useful in recurrent or treatment-resistant infections.
11. Treatment of Oral Candidiasis
Mild or localised oral candidiasis can often be treated with topical antifungal medications.
Nystatin oral suspension is commonly used because it acts locally against Candida organisms.
Clotrimazole preparations may also be used where available.
Moderate to severe oral candidiasis, or infection that does not respond to topical treatment, may require systemic fluconazole.
Management should also address predisposing factors, such as poor denture hygiene, uncontrolled diabetes or improper inhaled corticosteroid technique.
Oesophageal Candidiasis
12. Introduction to Oesophageal Candidiasis
Oesophageal candidiasis is a fungal infection involving the mucosal lining of the oesophagus.
It occurs particularly in patients with impaired cell-mediated immunity.
An important association is advanced HIV infection, although oesophageal candidiasis may also occur in patients receiving chemotherapy, corticosteroids or other immunosuppressive treatments.
Oesophageal candidiasis is generally more clinically significant than uncomplicated oral thrush because it suggests greater impairment of mucosal immune defence.
It is classified as an AIDS-defining condition in a person with HIV.
13. Pathogenesis of Oesophageal Candidiasis
Candida may colonise the oral cavity and upper gastrointestinal tract without causing disease.
When host immunity becomes impaired, the fungus can proliferate and invade the oesophageal mucosa.
Defective T-cell-mediated immunity is particularly important in susceptibility to oesophageal candidiasis.
In patients with advanced HIV infection, depletion of CD4-positive T lymphocytes increases the risk of opportunistic fungal infections.
Oesophageal candidiasis is especially associated with significant immunosuppression, often occurring when CD4 counts are below approximately 200 cells/µL.
14. Clinical Features of Oesophageal Candidiasis
The most characteristic symptom is odynophagia, meaning pain during swallowing.
Patients may also experience dysphagia, which is difficulty swallowing, and retrosternal discomfort.
Reduced oral intake may lead to dehydration, weight loss and nutritional impairment.
Oral thrush may be present simultaneously, but its absence does not exclude oesophageal candidiasis.
In an immunocompromised patient, particularly someone with advanced HIV infection, odynophagia should raise suspicion of oesophageal candidiasis.
15. Diagnosis of Oesophageal Candidiasis
Oesophageal candidiasis may be suspected clinically in a patient with compatible symptoms and relevant risk factors.
Upper gastrointestinal endoscopy can reveal white or yellowish adherent plaques along the oesophageal mucosa.
Brushings or biopsy specimens may demonstrate Candida organisms and evidence of mucosal invasion.
However, in a patient with a typical presentation and appropriate risk factors, clinicians may begin empirical antifungal treatment without immediate endoscopy.
Endoscopy is particularly important when symptoms are atypical, severe or fail to improve with appropriate treatment.
Other causes of infectious oesophagitis include cytomegalovirus and herpes simplex virus.
16. Treatment of Oesophageal Candidiasis
Oesophageal candidiasis requires systemic antifungal treatment because topical agents alone are inadequate.
Oral fluconazole is commonly used as first-line treatment when the patient can swallow and the organism is expected to be susceptible.
Intravenous fluconazole or an echinocandin may be appropriate when oral treatment is not possible or in selected resistant infections.
Treatment usually continues for approximately 14–21 days, depending on the clinical circumstances.
In patients with HIV infection, effective antiretroviral therapy is important for restoring immune function and reducing recurrence.
Vulvovaginal Candidiasis
17. Introduction to Vulvovaginal Candidiasis
Vulvovaginal candidiasis is a common fungal infection affecting the vulva and vagina.
It is often referred to as vaginal thrush.
The infection is usually caused by Candida albicans, although other Candida species can also be responsible.
Candida may be present in the vagina without causing symptoms. Symptomatic infection develops when fungal proliferation and the host inflammatory response produce vulvovaginal irritation.
Vulvovaginal candidiasis is common among women of reproductive age and may occur without any major underlying illness.
18. Risk Factors for Vulvovaginal Candidiasis
Several factors increase the likelihood of symptomatic vulvovaginal candidiasis.
Broad-spectrum antibiotics may disrupt the normal vaginal microbiota, allowing Candida to proliferate.
Pregnancy and other hormonal changes may increase susceptibility.
Poorly controlled diabetes mellitus is another important risk factor.
Immunosuppression may predispose to recurrent or severe infection.
However, many episodes occur in otherwise healthy individuals without an identifiable predisposing factor.
Vulvovaginal candidiasis is not generally classified as a sexually transmitted infection.
19. Clinical Features of Vulvovaginal Candidiasis
The most prominent symptom is vulval itching, often accompanied by irritation, burning and soreness.
Patients may develop vulval erythema, swelling and discomfort during sexual intercourse.
Dysuria may occur when urine contacts inflamed vulval tissues.
A characteristic finding is thick, white, curd-like vaginal discharge.
Unlike bacterial vaginosis, vulvovaginal candidiasis does not typically produce a strong fishy odour.
Vaginal pH usually remains within the normal acidic range, commonly 4.5 or below.
20. Diagnosis of Vulvovaginal Candidiasis
Diagnosis is based on symptoms, examination findings and, when appropriate, laboratory testing.
Microscopy of vaginal secretions may demonstrate budding yeast cells or pseudohyphae.
A potassium hydroxide preparation can help visualise fungal structures.
Fungal culture or molecular testing may be useful in recurrent, complicated or treatment-resistant infections.
Because Candida can colonise the vagina without causing disease, a positive test should be interpreted alongside symptoms.
Persistent symptoms should prompt consideration of alternative diagnoses, including bacterial vaginosis, trichomoniasis and non-infectious vulvovaginal disorders.
21. Treatment of Vulvovaginal Candidiasis
Uncomplicated vulvovaginal candidiasis is commonly treated with topical azole antifungals or oral fluconazole.
Clotrimazole is a commonly used topical antifungal agent that can be administered as a vaginal pessary, tablet or cream.
Oral fluconazole is another effective treatment for uncomplicated infection in appropriate non-pregnant patients.
An important correction to the original notes is that the drug is clotrimazole, not co-trimazole.
Clotrimazole is an antifungal medication, whereas co-trimoxazole is an antibacterial combination containing trimethoprim and sulfamethoxazole.
During pregnancy, topical azole therapy for seven days is generally preferred, while oral fluconazole is avoided.
22. Recurrent Vulvovaginal Candidiasis
Recurrent vulvovaginal candidiasis is generally defined as three or more symptomatic episodes within one year.
It may be associated with diabetes mellitus, antibiotic exposure, immunosuppression or infection with less susceptible Candida species.
However, recurrent disease may also occur without an identifiable predisposing condition.
Management usually involves confirming the diagnosis, identifying the Candida species when appropriate and assessing possible contributing factors.
Patients with recurrent Candida albicans infection may require an initial extended treatment course followed by suppressive antifungal therapy.
Treatment should be individualised, particularly during pregnancy or when non-albicans Candida species are involved.
Disseminated and Invasive Candidiasis
23. Introduction to Disseminated Candidiasis
Disseminated candidiasis is a serious fungal infection in which Candida spreads beyond superficial mucosal surfaces and involves the bloodstream or internal organs.
Invasive candidiasis includes candidemia, which refers to Candida infection of the bloodstream, and deep-seated infections involving normally sterile tissues.
These infections occur predominantly in hospitalised or critically ill patients with significant predisposing factors.
Disseminated candidiasis is particularly important because it can cause severe sepsis, multiorgan dysfunction and death.
Unlike superficial oral or vaginal candidiasis, invasive candidiasis requires urgent systemic antifungal therapy.
24. Risk Factors for Invasive Candidiasis
Important risk factors include prolonged intensive care admission, broad-spectrum antibiotic use and central venous catheterisation.
Patients receiving total parenteral nutrition are at increased risk because intravenous access and nutrient-rich infusions may facilitate fungal bloodstream infection.
Abdominal surgery, gastrointestinal perforation and disruption of mucosal barriers can allow Candida to enter normally sterile sites.
Neutropenia, haematological malignancy, organ transplantation and immunosuppressive therapy are additional risk factors.
Invasive candidiasis can also occur in critically ill patients who are not classically immunocompromised.
25. Pathogenesis of Invasive Candidiasis
Candida may enter the bloodstream through damaged gastrointestinal mucosa, infected intravascular catheters or other disrupted tissue barriers.
Once in the circulation, Candida can disseminate to internal organs.
The kidneys, liver, spleen, heart, eyes and central nervous system may be affected.
Candida can also form biofilms on intravascular catheters and implanted medical devices.
Biofilm formation reduces susceptibility to host immune mechanisms and may make infections more difficult to eradicate.
For this reason, removal of an infected intravascular catheter or other source-control intervention may be necessary.
26. Clinical Features of Invasive Candidiasis
Patients with invasive candidiasis commonly develop fever, chills and signs of systemic infection.
The clinical presentation may resemble bacterial sepsis.
In critically ill patients, candidemia should be considered when fever or clinical deterioration persists despite appropriate antibacterial treatment, particularly when important risk factors are present.
Disseminated infection may produce organ-specific manifestations, such as endocarditis, intra-abdominal abscesses or other deep-seated infections.
The presentation is often non-specific, making early clinical recognition challenging.
27. Diagnosis of Invasive Candidiasis
Blood cultures are an important diagnostic investigation for candidemia.
However, blood cultures may be negative in some patients with deep-seated invasive candidiasis.
Species identification and antifungal susceptibility testing are important because resistance patterns vary among Candida species.
Additional investigations depend on the suspected site of infection.
Imaging may be required to identify intra-abdominal collections or other deep-seated complications.
Serum β-D-glucan testing may provide supportive evidence in selected circumstances, although it is not specific for Candida and can produce false-positive results.
28. Treatment of Invasive Candidiasis
Invasive candidiasis requires prompt systemic antifungal therapy.
Echinocandins, such as caspofungin, micafungin and anidulafungin, are commonly recommended as initial treatment for candidemia in adults.
These medications inhibit fungal β-1,3-D-glucan synthesis, disrupting fungal cell wall formation.
Fluconazole may be used in selected clinically stable patients when the organism is susceptible.
Treatment may be changed from an echinocandin to fluconazole after clinical improvement, clearance of bloodstream infection and confirmation of susceptibility.
Source control, including appropriate catheter removal or drainage of infected collections, is also important.
For uncomplicated candidemia, treatment generally continues for at least 14 days after documented bloodstream clearance and resolution of attributable symptoms, provided there are no metastatic complications.
Cryptococcus Species
29. Introduction to Cryptococcus
Cryptococcus is a genus of encapsulated yeasts capable of causing pulmonary infection and central nervous system disease.
The two most important pathogenic groups are Cryptococcus neoformans and Cryptococcus gattii.
Cryptococcus neoformans is particularly associated with opportunistic infection in patients with impaired cell-mediated immunity, including advanced HIV infection.
Cryptococcus gattii can cause disease in both immunocompromised and apparently immunocompetent individuals.
Cryptococcal infection is usually acquired through inhalation of environmental fungal particles.
The lungs are generally the initial site of infection, but the organism may spread through the bloodstream to the central nervous system.
30. Morphological Characteristics of Cryptococcus
Cryptococcus is a round or oval budding yeast characterised by a prominent polysaccharide capsule.
The capsule is an important virulence factor because it interferes with phagocytosis and helps the organism evade host immune responses.
Cryptococcus typically demonstrates narrow-based budding.
The polysaccharide capsule can be visualised using India ink staining, which produces a clear halo around the yeast against a dark background.
However, India ink microscopy is less sensitive than modern cryptococcal antigen testing, particularly when fungal burden is low.
Cryptococcus also produces melanin through the activity of laccase, which contributes to resistance against oxidative stress.
31. Transmission of Cryptococcal Infection
Cryptococcal infection is generally acquired by inhalation of environmental fungal particles.
Cryptococcus neoformans has historically been associated with soil contaminated by bird droppings, particularly pigeon droppings.
Cryptococcus gattii has been associated with certain trees and environmental habitats.
Inhaled fungal particles enter the respiratory tract and may reach the alveoli.
Cryptococcosis is not usually transmitted directly from person to person.
The development of clinical disease depends largely on the host immune response and the pathogenic characteristics of the organism.
32. Pathogenesis of Cryptococcosis
Following inhalation, Cryptococcus may establish infection within the lungs.
In immunocompetent individuals, the immune response may contain the organism, sometimes resulting in a localised pulmonary nodule or granulomatous lesion.
The infection may remain asymptomatic or become clinically apparent.
In individuals with impaired cell-mediated immunity, Cryptococcus may proliferate and enter the bloodstream.
Haematogenous dissemination can lead to infection of the central nervous system.
Cryptococcus has a particular tendency to cause meningitis or meningoencephalitis, which may develop gradually over days to weeks.
Pulmonary Cryptococcosis
33. Introduction to Pulmonary Cryptococcosis
Pulmonary cryptococcosis usually represents the initial clinical manifestation of cryptococcal infection.
The organism enters the lungs through inhalation and may produce a localised inflammatory response.
In healthy individuals, infection may be asymptomatic or confined to a small pulmonary nodule.
In immunocompromised patients, pulmonary disease may become extensive and progress to disseminated infection.
The original notes correctly identify the lung as the usual primary focus of infection.
However, pulmonary cryptococcosis does not always produce a granuloma, particularly in severely immunosuppressed patients.
34. Clinical Features of Pulmonary Cryptococcosis
Pulmonary cryptococcosis may be asymptomatic or produce mild respiratory symptoms.
Patients may develop cough, fever, chest discomfort, breathlessness or weight loss.
Chest imaging may reveal solitary or multiple pulmonary nodules, consolidation, masses or diffuse infiltrates.
Some lesions may resemble tuberculosis or malignancy.
Severe pulmonary cryptococcosis can cause respiratory failure, particularly in immunocompromised individuals.
The presence of pulmonary cryptococcosis should prompt consideration of possible dissemination in patients with significant immune dysfunction.
35. Diagnosis of Pulmonary Cryptococcosis
Diagnosis may involve respiratory cultures, histopathology and cryptococcal antigen testing.
Chest radiography or CT can identify pulmonary abnormalities but cannot establish the diagnosis independently.
Tissue biopsy may demonstrate encapsulated budding yeasts and granulomatous inflammation.
Cryptococcal antigen testing may be positive in patients with more extensive or disseminated disease.
In patients with advanced immunosuppression, additional evaluation for central nervous system involvement may be necessary even when neurological symptoms are absent.
Cryptococcal Meningitis and Meningoencephalitis
36. Introduction to Cryptococcal Meningitis
Cryptococcal meningitis is a serious fungal infection involving the meninges and sometimes the brain parenchyma.
It usually develops after Cryptococcus spreads from the lungs through the bloodstream.
The condition is particularly associated with advanced HIV infection, especially when CD4-positive T-cell counts are below approximately 100 cells/µL.
Cryptococcal meningitis may also occur in organ transplant recipients, patients receiving immunosuppressive therapy and individuals with other forms of impaired cell-mediated immunity.
Unlike acute bacterial meningitis, cryptococcal meningitis often has a subacute or chronic presentation.
37. Pathogenesis of Cryptococcal Meningoencephalitis
After entering the bloodstream, Cryptococcus can cross the blood–brain barrier and establish infection within the central nervous system.
The polysaccharide capsule helps the fungus evade immune clearance.
The organism may accumulate within the meninges and perivascular spaces, producing inflammation and interfering with normal cerebrospinal fluid circulation.
A major complication is raised intracranial pressure, which can occur because of impaired cerebrospinal fluid resorption.
Raised intracranial pressure is an important cause of neurological deterioration and death in cryptococcal meningitis.
38. Clinical Features of Cryptococcal Meningitis
Cryptococcal meningitis typically develops gradually over several days or weeks.
Patients commonly present with persistent headache, fever, nausea, vomiting and malaise.
Neck stiffness and photophobia may occur, but classical meningeal signs can be absent, particularly in severely immunocompromised patients.
Progressive disease may produce confusion, behavioural changes, altered consciousness and seizures.
Cranial nerve palsies, visual disturbances and papilloedema may occur when intracranial pressure becomes elevated.
The characteristic clinical pattern is subacute headache and fever in an immunocompromised patient, particularly someone with advanced HIV infection.
39. Cerebrospinal Fluid Findings in Cryptococcal Meningitis
Lumbar puncture is a central investigation in suspected cryptococcal meningitis, provided it can be performed safely.
Cerebrospinal fluid may demonstrate an elevated opening pressure.
Typical findings include increased protein concentration, reduced CSF glucose and a lymphocytic pleocytosis.
However, patients with advanced HIV infection may have relatively few CSF inflammatory cells despite severe infection.
Therefore, a low CSF white cell count does not exclude cryptococcal meningitis.
The most important diagnostic test is cryptococcal antigen detection, which is highly sensitive and specific in appropriate clinical settings.
40. Cryptococcal Antigen Testing
Cryptococcal antigen testing detects components of the fungal polysaccharide capsule.
Testing can be performed on cerebrospinal fluid and serum.
The lateral flow assay is widely used because it is rapid and highly sensitive.
A positive CSF cryptococcal antigen test strongly supports the diagnosis of cryptococcal meningitis in a compatible clinical setting.
Serum cryptococcal antigen testing is also useful for detecting cryptococcal infection in high-risk patients, including selected individuals with advanced HIV infection.
Fungal culture remains important for confirming viable organisms and assessing microbiological response.
41. India Ink Staining
India ink staining is a classical microbiological method used to identify Cryptococcus in cerebrospinal fluid.
The dark background highlights the unstained polysaccharide capsule, producing a clear halo around the budding yeast.
This appearance is characteristic of encapsulated Cryptococcus.
However, India ink microscopy is less sensitive than cryptococcal antigen testing and may fail to detect infection when the fungal burden is low.
Therefore, a negative India ink preparation does not exclude cryptococcal meningitis.
The important examination association is Cryptococcus = encapsulated, narrow-based budding yeast with an India ink halo.
42. Treatment of Cryptococcal Meningitis
Cryptococcal meningitis requires prolonged systemic antifungal treatment.
Treatment is commonly divided into induction, consolidation and maintenance phases.
Induction therapy aims to reduce fungal burden rapidly. For HIV-associated cryptococcal meningitis, preferred induction regimens depend on available resources and clinical guidance, and may include liposomal amphotericin B combined with flucytosine and fluconazole, or an amphotericin-based regimen with flucytosine.
Consolidation therapy usually involves fluconazole at a higher dose for a defined period.
Maintenance therapy uses a lower dose of fluconazole to prevent relapse until adequate immune recovery has occurred.
Treatment must also address raised intracranial pressure and underlying immunosuppression.
43. Amphotericin B in Cryptococcal Meningitis
Amphotericin B is a polyene antifungal medication that binds to ergosterol within fungal cell membranes.
This disrupts membrane integrity and produces fungal cell injury.
Liposomal amphotericin B is often preferred where available because it generally causes less nephrotoxicity than conventional amphotericin B deoxycholate.
Important adverse effects include kidney injury, hypokalaemia, hypomagnesaemia and infusion-related reactions.
Renal function and electrolyte concentrations require monitoring during treatment.
Amphotericin B is commonly combined with flucytosine during induction therapy because the combination improves fungal clearance.
44. Flucytosine
Flucytosine is an antifungal medication particularly important in the treatment of cryptococcal meningitis.
It enters fungal cells and is converted into metabolites that interfere with fungal nucleic acid synthesis.
Flucytosine is generally used in combination with amphotericin B rather than as monotherapy because resistance can develop rapidly when it is used alone.
Important adverse effects include bone marrow suppression, hepatotoxicity and gastrointestinal disturbances.
Dose adjustment is required in renal impairment, and drug-level monitoring may be appropriate where available.
45. Fluconazole
Fluconazole is a triazole antifungal medication that inhibits fungal ergosterol synthesis.
It acts by inhibiting the fungal enzyme 14-alpha-demethylase, disrupting normal cell membrane formation.
Fluconazole has good oral bioavailability and penetrates cerebrospinal fluid effectively.
It is therefore important in the consolidation and maintenance phases of cryptococcal meningitis treatment.
Fluconazole is also used for oral, oesophageal and vulvovaginal candidiasis when appropriate.
Important adverse effects include hepatotoxicity, QT prolongation and drug interactions.
46. Management of Raised Intracranial Pressure
Raised intracranial pressure is one of the most important complications of cryptococcal meningitis.
It may cause severe headache, vomiting, visual impairment, cranial nerve palsies and deterioration in consciousness.
Opening pressure should be measured during lumbar puncture whenever feasible.
Patients with symptomatic elevated intracranial pressure often require repeated therapeutic lumbar punctures to remove cerebrospinal fluid and reduce pressure.
In refractory cases, a lumbar drain or cerebrospinal fluid shunt may be necessary.
Corticosteroids, acetazolamide and mannitol are not routinely recommended for managing cryptococcal intracranial hypertension because they have not shown consistent benefit and may cause harm.
47. Cryptococcal Meningitis and HIV
Cryptococcal meningitis is a major opportunistic infection in patients with advanced HIV disease.
The risk increases substantially when CD4-positive T-cell counts become severely reduced.
Antiretroviral therapy is essential for long-term immune recovery, but the timing of initiation is important.
In patients with HIV-associated cryptococcal meningitis, starting antiretroviral therapy immediately may increase the risk of severe immune reconstitution inflammatory syndrome and mortality.
Therefore, antiretroviral therapy is generally deferred for approximately 4–6 weeks after initiation of antifungal treatment, with timing guided by clinical circumstances and specialist recommendations.
Comparison of Candida and Cryptococcus
48. Candida – Clinical Pattern
Candida is an opportunistic yeast that commonly colonises the mouth, gastrointestinal tract, vagina and skin.
It can cause superficial mucosal infections such as oral thrush, oesophageal candidiasis and vulvovaginal candidiasis.
Candida may also enter the bloodstream and cause invasive candidiasis, particularly in critically ill or immunocompromised patients.
Microscopy commonly demonstrates budding yeast cells and, with certain species, pseudohyphae or true hyphae.
Treatment depends on the site and severity of infection, ranging from topical nystatin or clotrimazole to systemic fluconazole or echinocandins.
49. Cryptococcus – Clinical Pattern
Cryptococcus is an encapsulated yeast acquired primarily through inhalation.
The lungs are generally the initial site of infection, where the organism may produce pulmonary nodules, granulomatous lesions or more extensive pulmonary disease.
Haematogenous dissemination may lead to cryptococcal meningitis or meningoencephalitis.
Cryptococcal meningitis is particularly associated with advanced HIV infection and impaired cell-mediated immunity.
The organism classically demonstrates narrow-based budding and a prominent polysaccharide capsule.
Diagnosis relies heavily on cryptococcal antigen testing, while treatment of meningitis requires combination antifungal therapy and management of intracranial pressure.
50. Important Corrections to the Original Notes
The original statement that Candida causes plaque-like oral lesions is correct. More specifically, pseudomembranous oral candidiasis produces white plaques that can often be scraped away.
The association of oral candidiasis with antibiotics, corticosteroids and immunosuppression is also correct.
Oesophageal candidiasis is strongly associated with advanced HIV infection, but it can also occur in patients receiving corticosteroids, chemotherapy or other immunosuppressive treatments.
Vulvovaginal candidiasis is common in women and may be treated with topical clotrimazole or oral fluconazole in appropriate circumstances.
The correct antifungal drug is clotrimazole, not co-trimazole. Co-trimoxazole is an antibacterial combination and is not a standard treatment for vaginal candidiasis.
Disseminated candidiasis is associated with immunosuppression but also occurs in critically ill patients with central venous catheters, abdominal surgery or other disruptions of normal barriers.
The original statement that Cryptococcus may produce a pulmonary granuloma is correct, although granuloma formation is not universal.
The statement that Cryptococcus can spread through the bloodstream and cause subacute or chronic meningoencephalitis is also correct and represents one of the most important clinical features of cryptococcal infection.
51. Important Fungal Infections – Note Form
Oral candidiasis produces creamy-white plaques in the oral cavity and is associated with antibiotic use, corticosteroids, diabetes and immunosuppression. Treatment commonly involves topical nystatin or systemic fluconazole when appropriate.
Oesophageal candidiasis is particularly associated with advanced HIV infection and other causes of impaired cell-mediated immunity. It commonly causes odynophagia and dysphagia and requires systemic antifungal treatment.
Vulvovaginal candidiasis causes vulval itching, irritation and thick white vaginal discharge. Treatment commonly involves topical clotrimazole or oral fluconazole in suitable non-pregnant patients.
Disseminated candidiasis occurs when Candida invades the bloodstream or internal organs. It is particularly associated with critical illness, intravascular catheters, abdominal surgery and immunosuppression. Echinocandins are commonly used as initial systemic treatment.
Pulmonary cryptococcosis usually develops following inhalation of Cryptococcus and may cause pulmonary nodules, granulomatous lesions or pneumonia.
Cryptococcal meningitis develops when Cryptococcus spreads to the central nervous system. It is particularly associated with advanced HIV infection and commonly produces subacute headache, fever, confusion and raised intracranial pressure.
52. Important Antifungal Drug Associations
Nystatin is a polyene antifungal medication used mainly for superficial Candida infections, particularly oral candidiasis.
Clotrimazole is an azole antifungal used for superficial fungal infections, including vulvovaginal candidiasis.
Fluconazole inhibits ergosterol synthesis and is important in oral, oesophageal and vulvovaginal candidiasis, as well as the consolidation and maintenance phases of cryptococcal meningitis.
Echinocandins inhibit fungal β-1,3-D-glucan synthesis and are commonly used as initial therapy for invasive candidiasis.
Amphotericin B binds fungal ergosterol and is important in severe invasive fungal infections, including cryptococcal meningitis.
Flucytosine interferes with fungal nucleic acid synthesis and is used in combination regimens for cryptococcal meningitis.
Key Clinical Pattern
The major distinction is that Candida commonly causes mucosal and invasive bloodstream infections, whereas Cryptococcus is particularly associated with pulmonary infection and subacute or chronic meningoencephalitis.
Candida albicans → Oral thrush → Removable white plaques in the mouth.
Candida + antibiotics or inhaled corticosteroids → Increased risk of oral candidiasis.
Candida + advanced HIV → Oesophageal candidiasis with odynophagia.
Candida + vulval itching and thick white discharge → Vulvovaginal candidiasis.
Candida + critical illness or central venous catheter → Candidemia and invasive candidiasis.
Cryptococcus neoformans → Encapsulated, narrow-based budding yeast.
Cryptococcus + inhalation → Primary pulmonary infection.
Cryptococcus + haematogenous spread → Meningitis or meningoencephalitis.
Cryptococcus + advanced HIV + subacute headache → Suspect cryptococcal meningitis.
Cryptococcal meningitis → Positive cryptococcal antigen, often elevated CSF opening pressure, and treatment with combination antifungal therapy.
For examinations, remember that Candida albicans commonly forms budding yeast cells and pseudohyphae, while Cryptococcus is distinguished by its prominent polysaccharide capsule and association with meningitis.